Neurochemistry changes associated with mutations in familial Parkinson's disease

Current Medicinal Chemistry

Volumn 17, Issue 35, 2010, Pages 4378-4391

  Siddique, M M ^a   Tan, E K ^a,b,c,d  

^a Singapore Health Services   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Mitochondrial dysfunction; Parkinson's disease (PD); Protein aggregation

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DJ 1 PROTEIN; HEAT SHOCK PROTEIN; LEUCINE RICH REPEAT KINASE 2; MEMBRANE PROTEIN; PARKIN; PINK1 PROTEIN; PROTEASOME; PROTEIN P53; ROTENONE; UCHL1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENE MUTATION; HEREDITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; NEUROCHEMISTRY; NEUROPATHOLOGY; NITROSATIVE STRESS; NONHUMAN; OXIDATION; PARKINSON DISEASE; PARKINSONISM; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

HUMANS; MUTATION; NERVOUS SYSTEM; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

EID: 78650631774     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793361270     Document Type: Article

References (157)

1. Tan, E. K.; Jankovic, J. Genetic testing in Parkinson disease: promises and pitfalls. Arch. Neurol., 2006, 63, 1232-7.
2. Tan, E. K. The role of common genetic risk variants in Parkinson disease. Clin. Genet., 2007, 72, 387-93.
3. Outeiro, T. F.; Lindquist, S. Yeast cells provide insight into α-synuclein biology and pathobiology. Science, 2003, 302, 1772-5.
4. Murphy, D. D.; Rueter, S. M.; Trojanowski, J. Q.; Lee, V. M. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci., 2000, 20, 3214-20.
5. Abeliovich, A.; Schmitz, Y.; Fariñas, I.; Choi-Lundberg, D.; Ho, W. H,; Castillo, P. E.; Shinsky, N.; Verdugo, J. M.; Armanini, M.; Ryan, A.; Hynes, M.; Phillips, H.; Sulzer, D.; Rosenthal, A. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 2000, 25, 239-52.
6. Utton, M. A.; Noble, W. J.; Hill, J. E.; Anderton, B. H.; Hanger, D. P. Molecular motors implicated in the axonal transport of tau and α-synuclein. J. Cell Sci., 2005, 118, 4645-54.
7. Saha, A. R.; Hill, J.; Utton,. M. A.; Asuni, A. A.; Ackerley, S.; Grierson, A. J.; Miller, C. C.; Davies, A. M.; Buchman, V. L.; Anderton, B. H.; Hanger, D. P. Parkinson's disease α-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci., 2004, 117, 1017-24.
8. Lee, S. S.; Kim, Y. M.; Junn, E.; Lee, G. Park KH, Tanaka M, Ronchettib RD, Quezadob MM, Mouradian MM. Cell cycle aberrations by α-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies. Neurobiol. Aging, 2003, 24, 687-6.
9. Okochi, M.; Walter, J.; Koyama, A.; Nakajo, S.; Baba, M.; Iwatsubo, T.; Meijer, L.; Kahle, P. J.; Haass, C. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J. Biol. Chem., 2000, 75, 390-7.
10. Li, W.; West, N.; Colla, E.; Pletnikova, O.; Troncoso, J. C.; Marsh, L.; Dawson, T. M.; Jäkälä, P.; Hartmann, T.; Price, D. L.; Lee, M. K. Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. USA, 2005, 102, 2162-7.
11. Michell, A. W.; Tofaris, G. K.; Gossage, H.; Tyers, P.; Spillantini, M. G.; Barker, R. A. The effect of truncated human α-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant., 2007, 16, 461-74.
12. Rott, R.; Szargel, R.; Haskin, J.; Shani, V.; Shainskaya, A.; Manov, I.; Liani, E.; Avraham, E.; Engelender, S. Monoubiquitylation of α-Synuclein by Seven in Absentia Homolog (SIAH) Promotes Its Aggregation in Dopaminergic Cells. J. Biol. Chem., 2008, 283, 3316-28.
13. Lee, J. T.; Wheeler, T. C.; Li, L.; Chin, L. S. Ubiquitination of α-synuclein by Siah-1 promotes α-synuclein aggregation and apoptotic cell death. Hum. Mol. Genet., 2008, 17, 906-17.
14. Lee, S. J. Origins and effects of extracellular α-synuclein: implications in Parkinson's disease. J. Mol. Neurosci., 2008, 34, 17-22.
15. Reynolds, A. D.; Kadiu, I.; Garg, S. K.; Glanzer, J. G.; Nordgren, T.; Ciborowski, P.; Banerjee, R.; Gendelman, H. E. Nitrated α-synuclein and microglial neuroregulatory activities. J. Neuroimmune. Pharmacol., 2008, 3, 59-74.
16. Takahashi, M.; Ko, L. W.; Kulathingal, J.; Jiang, P.; Sevlever, D.; Yen, S. H. Oxidative stress-induced phosphorylation, degradation and aggregation of α-synuclein are linked to upregulated CK2 and cathepsin D. Eur. J. Neurosci. 2007, 26, 863-74.
17. Windisch, M.; Wolf, H. J.; Hutter-Paier, B.; Hofmeister, A.; Wronski, R. Is α-synuclein pathology a target for treatment of neurodegenerative disorders? Curr. Alzheimer Res., 2007, 4, 446-57.
18. Gitler, A. D.; Bevis, B. J.; Shorter, J.; Strathearn, K. E.; Hamamichi, S.; Su, L. J.; Caldwell, K. A.; Caldwell, G. A.; Rochet, J. C.; McCaffery, J. M.; Barlowe, C.; Lindquist, S. The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. USA, 2008, 105, 145-50.
19. Park, S. S.; Schulz, E. M.; Lee, D. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by α-synuclein. Eur. J. Neurosci., 2007, 26, 3104-12.
20. Guo, J. T.; Chen, A. Q.; Kong, Q.; Zhu, H.; Ma, C. M.; Qin, C. Inhibition of Vesicular Monoamine Transporter-2 Activity in α-Synuclein Stably Transfected SH-SY5Y Cells. Cell Mol. Neurobiol., 2008, 28, 35-47.
21. Danzer, K. M.; Haasen, D.; Karow, A. R.; Moussaud, S.; Habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.; Kostka, M. Different species of α-synuclein oligomers induce calcium influx and seeding. J. Neurosci., 2007, 27, 9220-32.
22. Mazzulli, J. R.; Mishizen, A. J.; Giasson, B. I.; Lynch, D. R.; Thomas, S. A.; Nakashima, A.; Nagatsu, T.; Ota, A.; Ischiropoulos, H. Cytosolic catechols inhibit α-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci., 2006, 26, 10068-78.
23. Yuan, Y.; Jin, J.; Yang, B.; Zhang, W.; Hu, J.; Zhang, Y.; Chen, N. H. Overexpressed α-synuclein regulated the nuclear factor-kappa B signal pathway. Cell Mol. Neurobiol., 2008, 28, 21-33.
24. Imai, Y.; Soda, M.; Takahashi, R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem., 2000, 275, 35661-4.
25. Shimura, H.; Hattori, N.; Kubo, S.; Mizuno, Y.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Iwai, K.; Chiba, T.; Tanaka, K.; Suzuki, T. Familial Parkinson disease gene product, parkin, is a ubiquitinprotein ligase. Nat. Genet., 2000, 25, 302-5.
26. West, A. B.; Dawson, V. L.; Dawson, T. M. To die or grow: Parkinson's disease and cancer. Trends Neurosci., 2005, 28, 348-52.
27. West, A. B.; Kapatos, G.; O'Farrell, C.; Gonzalez-de-Chavez, F.; Chiu, K.; Farrer, M. J.; Maidment, N. T. N-myc regulates parkin expression. J. Biol. Chem. 2004, 279, 28896-902.
28. Feng, J. Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist, 2006, 12, 469-76.
29. Yao, D.; Zezong, G.; Tomohiro, N.; Zhong-Qing, S.; Yuliang, M.; Benjamin, G.; Palmer, L. A.; Rockenstein, E. M.; Zhang, Z.; Masliah, E.; Uehara, T.; Lipton, S. A. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. USA, 2004, 101, 10810-4.
30. Steece-Collier, K.; Maries, E.; Kordower, J. H. Etiology of Parkinson's disease: Genetics and environment revisited. Proc. Natl. Acad. Sci. USA, 2002, 99, 13972-4.
31. La Voie, M. J.; Ostaszewski, B. L.; Weihofen, A.; Schlossmacher, M. G.; Selkoe, D. J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med., 2005, 11, 1214-21.
32. Tan, E. K.; Puong, K. Y.; Chan, D. K.; Yew, K.; Fook-Chong, S.; Shen, H.; Ng, P. W.; Woo, J.; Yuen, Y.; Pavanni, R.; Wong, M. C.; Puvan, K.; Zhao, Y. Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association. Hum. Genet., 2005a, 118, 484-8.
33. Tan, E. K.; Shen, H.; Tan, J. M.; Lim, K. L.; Fook-Chong, S.; Hu, W. P.; Paterson, M. C.; Chandran, V. R.; Yew, K.; Tan, C.; Yuen, Y.; Pavanni, R.; Wong, M. C.; Puvan, K.; Zhao, Y. Differential expression of splice variant and wild-type parkin in sporadic Parkinson's disease. Neurogenetics, 2005b, 6, 179-84.
34. Savitt, J. M.; Dawson, V. M.; Dawson, T. M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest., 2006, 116, 1744-54.
35. Wiedemeyer, R.; Westermann, F.; Wittke, I.; Nowock, J.; Schwab, M. Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene, 2003, 22, 401-11.
36. Huynh, D. P.; Nguyen, D. T.; Pulst-Korenberg, J. B.; Brice, A.; Pulst, S. M. Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Exp. Neurol., 2007, 203, 531-41.
37. Aslanukov, A.; Bhowmick, R.; Guruju, M.; Oswald, J.; Raz, D.; Bush, R. A.; Sieving, P. A.; Lu, X.; Bock, C. B.; Ferreira, P. A. Ran BP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of Ran BP2 causes deficits in glucose metabolism. PLoS. Genet., 2006, 2, e177.
38. Renner, O.; Fominaya, J.; Alonso, S.; Blanco-Aparicio, C.; Leal, J. F.; Carnero, A. Mst1, Ran BP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis, 2007, 28, 1418-25.
39. Um, J. W.; Min, D. S.; Rhim, H.; Kim, J.; Paik, S. R; Chung, K. C. Parkin ubiquitinates and promotes the degradation of ran BP2. J. Biol. Chem., 2006, 281, 3595-603.
40. Solano, S. M.; Miller, D. W.; Augood, S. J.; Young, A. B.; Penney, J. B. Expression of α-synuclein, parkin, and ubiquitin carboxyterminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann. Neurol., 2000, 47, 201-10.
41. Gong, B.; Cao, Z.; Zheng, P.; Vitolo, O. V.; Liu, S.; Staniszewski, A.; Moolman, D.; Zhang, H.; Shelanski, M.; Arancio, O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell, 2006, 126, 775-88.
42. Barrachina, M.; Castaño, E.; Dalfó, E.; Maes, T.; Buesa, C.; Ferrer, I. Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. Neurobiol. Dis. 2006, 22, 265-73.
43. Leroy, E.; Boyer, R.; Auburger, G.; Leube, B.; Ulm, G.; Mezey, E.; Harta, G.; Brownstein, M. J.; Jonnalagada, S.; Chernova, T.; Dehejia, A.; Lavedan, C.; Gasser, T.; Steinbach, P. J.; Wilkinson, K. D.; Plymeropoulos, M. H. The ubiquitin pathway in Parkinson's disease. Nature, 1998, 395, 451-2.
44. Nishikawa, K.; Li, H.; Kawamura, R.; Osaka, H.; Wang, Y. L.; Hara, Y.; Hirokawa, T.; Manago, Y.; Amano, T.; Noda, M.; Aoki, S.; Wada, K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biophys. Res. Commun., 2003, 304, 176-83.
45. Lansbury, P. T.; Brice, A. Genetics of Parkinson's disease and biochemical studies of implicated gene products, Curr. Opin. Genet. Dev., 2002, 13, 299-06.
46. Setsuie, R.; Wang, Y. L.; Mochizuki, H.; Osaka, H.; Hayakawa, H.; Ichihara, N.; Li, H.; Furuta, A.; Sano, Y.; Sun, Y. J.; Kwon, J.; Kabuta, T.; Yoshimi, K.; Aoki, S.; Mizuno, Y.; Noda, M.; Wada, K. Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant. Neurochem. Int., 2007, 50, 119-29.
47. Osaka, H.; Wang, Y. L.; Takada, K.; Takizawa, S.; Setsuie, R.; Li, H.; Sato, Y.; Nishikawa, K.; Sun, Y. J.; Sakurai, M.; Harada, T.; Hara, Y.; Kimura, I.; Chiba, S.; Namikawa, K.; Kiyama, H.; Noda, M.; Aoki, S.; Wada, K. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet., 2003, 12, 1945-58.
48. Saigoh, K.; Wang, Y. L.; Suh, J. G.; Yamanishi, T.; Sakai, Y.; Kiyosawa, H.; Harada, T.; Ichihara, N.; Wakana, S.; Kikuchi, T.; Wada, K. Intragenic deletion in the gene encoding ubiquitin carboxyterminal hydrolase in gad mice. Nat. Genet., 1999, 23, 47-51.
49. Shen, H.; Sikorska, M.; LeBlanc, J.; Walker, P. R.; Liu, Q. Y. Oxidative stress regulated expression of Ubiquitin Carboxyl-terminal Hydrolase-L1: Role in cell survival. Apoptosis, 2006, 11, 1049-59.
50. Gandhi, S.; Muqit, M. M.; Stanyer, L.; Healy, D. G.; Abou-Sleiman, P. M.; Hargreaves, I.; Heales, S.; Ganguly, M.; Parsons, L.; Lees, A. J.; Latchman, D. S.; Holton, J. L.; Wood, N. W.; Revesz, T. PINK1 protein in normal human brain and Parkinson's disease. Brain, 2006, 129, 1720-31.
51. Wang, H. L.; Chou, A. H.; Yeh, T. H.; Li, A. H.; Chen, Y. L.; Kuo, Y. L.; Tsai, S. R.; Yu, S. T. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol. Dis., 2007, 28, 216-26.
52. Clark, I. E.; Dodson, M. W.; Jiang, C.; Cao, J. H.; Huh, J. R.; Seol, J. H.; Yoo, S. J.; Hay, B. A.; Guo, M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature, 2006, 441, 1162-6.
53. Abou-Sleiman, P. M.; Muqit, M. M.; McDonald, N. Q.; Yang, Y. X.; Gandhi, S.; Healy, D. G.; Harvey, K.; Harvey, R. J.; Deas, E.; Bhatia, K.; Quinn, N.; Lees, A.; Latchman, D. S.; Wood, N. W. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann. Neurol., 2006, 60, 414-9.
54. Petit, A.; Kawarai, T.; Paitel, E.; Sanjo, N.; Maj, M.; Scheid, M.; Chen, F.; Gu, Y.; Hasegawa, H.; Salehi-Rad, S.; Wang, L.; Rogaeva, E.; Fraser, P.; Robinson, B.; St George-Hyslop, P.; Tandon, A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protectiveeffect abrogated by Parkinson disease-related mutations. J. Biol. Chem., 2005, 280, 34025-32.
55. Pridgeon, J. W.; Olzmann, J. A.; Chin, L. S.; Li, L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS. Biol., 2007, 7, e172.
56. Masuda, Y.; Shima, G.; Aiuchi, T.; Horie, M.; Hori, K.; Nakajo, S.; Kajimoto, S.; Shibayama-Imazu, T.; Nakaya, K. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J. Biol. Chem., 2004, 279, 42503-15.
57. Hua, G.; Zhang, Q.; Fan, Z. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J. Biol. Chem., 2007, 282, 20553-60.
58. Vande, W. L.; Lamkanfi, M.; Vandenabeele, P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ., 2008, 15, 453-60.
59. Tun, C.; Guo, W.; Nguyen, H.; Yun, B.; Libby, R. T.; Morrison, R. S.; Garden, G. A. Activation of the extrinsic caspase pathway in cultured cortical neurons requires p53-mediated down-regulation of the X-linked inhibitor of apoptosis protein to induce apoptosis. J. Neurochem., 2007, 102, 1206-19.
60. Plun-Favreau, H.; Klupsch, K.; Moisoi, N.; Gandhi, S.; Kjaer, S.; Frith, D.; Harvey, K.; Deas, E.; Harvey, R. J.; McDonald, N.; Wood, N. W.; Martins, L. M.; Downward, J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol., 2007, 9, 1227-9.
61. Yang, L.; Sun, M.; Sun, X. M.; Cheng, G. Z.; Nicosia, S. V.; Cheng, J. Q. Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine 212. J. Biol. Chem., 2007, 282, 10981-7.
62. Dodson, M. W.; Guo, M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr. Opin. Neurobiol., 2007, 17, 331-7.
63. Zhou, W.; Freed, C. R. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T α-synuclein toxicity. J. Biol., Chem., 2005, 280, 43150-8.
64. Canet-Avilés, R. M.; Wilson, M. A.; Miller, D. W.; Ahmad, R.; McLendon, C.; Bandyopadhyay, S.; Baptista, M. J.; Ringe, D.; Petsko, G. A.; Cookson, M. R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci., 2004, 101, 9103-8.
65. Taira, T.; Saito, Y.; Niki, T.; Iguchi-Ariga, S. M.; Takahashi, K.; Ariga, H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO. Rep., 2004, 5, 213-8.
66. Hedrich, K.; Djarmati, A.; Schäfer, N.; Hering, R.; Wellenbrock, C.; Weiss, P. H.,; Hilker, R.; Vieregge, P.; Ozelius, L. J.; Heutink, P.; Bonifati, V.; Schwinger, E.; Lang, A. E.; Noth, J.; Bressman, S. B.; Pramstaller, P. P.; Riess, O.; Klein, C. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in earlyonset Parkinson disease. Neurology, 2004, 62, 389-94.
67. Bandyopadhyay, S.; Cookson, M. R. Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol. Biol., 2004, 4, 6.
68. Zhang, L.; Shimoji, M.; Thomas, B.; Moore, D. J.; Yu, S. W.; Marupudi, N. I.; Torp, R.; Torgner, I. A.; Ottersen, O. P.; Dawson, T. M.; Dawson, V. L. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet., 2005, 14, 2063-73.
69. Hering, R.; Strauss, K. M.; Tao, X.; Bauer, A.; Woitalla, D.; Mietz, E. M.; Petrovic, S.; Bauer, P.; Schaible, W.; Müller, T.; Schöls, L.; Klein, C.; Berg, D.; Meyer, P. T.; Schulz, J. B.; Wollnik, B.; Tong, L.; Krüger, R.; Riess, O. Novel homozygous p. E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum. Mutat., 2004, 24, 321-9.
70. Tang, B.; Xiong, H.; Sun, P.; Zhang, Y.; Wang, D.; Hu, Z.; Zhu, Z.; Ma, H.; Pan, Q.; Xia, J. H.; Xia, K.; Zhang, Z. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum. Mol. Genet., 2006, 15, 1816-25.
71. Moore, D. J.; West, A. B.; Dawson, V. L.; Dawson, T. M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 2005, 28, 57-87.
72. Kim, R. H.; Smith, P. D.; Aleyasin, H.; Hayley, S.; Mount, M. P.; Pownall, S.; Wakeham, A.; You-Ten, A. J.; Kalia, S. K.; Horne, P.; Westaway, D.; Lozano, A. M.; Anisman, H.; Park, D. S.; Mak, T. W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U S A, 2005, 102, 5215-20.
73. Meulener, M.; Whitworth, A. J.; Armstrong-Gold, C. E.; Rizzu, P.; Heutink, P.; Wes, P. D.; Pallanck, L. J.; Bonini, N. M. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol., 2005, 15, 1572-7.
74. Yang, Y.; Gehrke, S.; Haque, M. E.; Imai, Y.; Kosek, J.; Yang, L.; Beal, M. F.; Nishimura, I.; Wakamatsu, K.; Ito, S.; Takahashi, R.; Lu, B. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl. Acad. Sci. U S A, 2005, 102, 13670-5.
75. Goldberg, M. S.; Pisani, A.; Haburcak, M.; Vortherms, T. A.; Kitada, T.; Costa, C.; Tong, Y.; Martella, G,; Tscherter, A.; Martins, A.; Bernardi, G.; Roth, B. L.; Pothos, E. N.; Calabresi, P.; Shen, J. Nigrostriatal dopaminergic deficits and hypokinesia caused by in activation of the familial Parkinsonism-linked gene DJ-1. Neuron, 2005, 45, 489-96.
76. Tan, E. K.; Sie, L.; Loong, S. Growth rate of patient-derived lymphoblastoid cells with LRRK2 mutations. Mol. Genet. Metab., 2008a, 95, 113.
77. Tan, E. K.; Tan, L. C.; Lim, H. Q.; Li, R.; Tang, M.; Yih, Y.; Pavanni, R.; Prakash, K. M.; Fook-Chong, S.; Zhao, Y. LRRK2 R1628P increases risk of Parkinson's disease: replication evidence. Hum. Genet., 2008b, 24, 287-8.
78. Ross, O. A.; Wu, Y. R.; Lee, M. C.; Funayama, M.; Chen, M. L.; Soto, A. I.; Mata, I. F.; Lee-Chen, G. J.; Chen, C. M.; Tang, M.; Zhao, Y.; Hattori, N.; Farrer, M. J.; Tan, E. K.; Wu, R. M. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol., 2008, 64, 88-92.
79. Tan, E. K.; Skipper, L. M. Pathogenic mutations in Parkinson disease. Hum. Mutat., 2007, 28, 641-53.
80. Lesage, S.; Dürr, A.; Tazir, M.; Lohmann, E.; Leutenegger, A. L.; Janin, S.; Pollak, P.; Brice, A. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med., 2006, 354, 422-3.
81. Farrer, M.; Stone, J.; Mata, I. F.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Strain, K.; J.; Maraganore, D. M. LRRK2 mutations in Parkinson disease. Neurology, 2005, 65, 738-40.
82. Higashi, S.; Moore, D. J.; Colebrooke, R. E.; Biskup, S.; Dawson, V. L.; Arai, H.; Dawson, T. M.; Emson, P. C. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem., 2007, 100, 368-81.
83. Melrose, H. L.; Kent, C. B.; Taylor, J. P.; Dachsel, J. C.; Hinkle, K. M.; Lincoln, S. J.; Mok, S. S.; Culvenor, J. G.; Masters, C. L.; Tyndall, G. M.; Bass, D. I.; Ahmed, Z.; Andorfer, C. A.; Ross, O. A.; Wszolek, Z. K.; Delldonne, A.; Dickson, D. W.; Farrer, M. J. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience, 2007, 147, 1047-58.
84. Giasson, B. I.; Covy, J. P.; Bonini, N. M.; Hurtig, H. I.; Farrer, M. J.; Trojanowski, J. Q.; van Deerlin, V. M. Biochemical and pathological characterization of Lrrk2. Ann. Neurol., 2006, 59, 315-22.
85. Li, X.; Tan, Y. C.; Poulose, S.; Olanow, C. W.; Huang, X. Y.; Yue, Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem., 2007, 103, 238-47.
86. West, A. B.; Moore, D. J.; Choi, C.; Andrabi, S. A.; Li, X.; Dikeman, D.; Biskup, S.; Zhang, Z.; Lim, K. H.; Dawson, V. L.; Dawson, T. M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 2007, 16, 223-32.
87. Guo, L.; Gandhi, P. N.; Wang, W.; Petersen, R. B.; Wilson-Delfosse, A. L.; Chen, S. G. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell. Res., 2007, 313, 3658-70.
88. Gloeckner, C. J.; Kinkl, N.; Schumacher, A.; Braun, R. J.; O'Neill, E.; Meitinger, T.; Kolch, W.; Prokisch, H.; Ueffing, M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet., 2006, 15, 223-32.
89. Cookson, M. R.; Dauer, W.; Dawson, T.; Fon, E. A.; Guo, M.; Shen, J. The roles of kinases in familial Parkinson's disease. J. Neurosci., 2007, 27, 11865-8.
90. Iaccarino, C.; Crosio, C.; Vitale, C.; Sanna, G.; Carri, M. T.; Barone, P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet., 2007, 16, 1319-26.
91. Greggio, E.; Jain, S.; Kingsbury, A.; Bandopadhyay, R.; Lewis, P.; Kaganovich, A.; van der Brug, M. P.; Beilina, A.; Blackinton, J.; Thomas, K. J.; Ahmad, R.; Miller, D. W.; Kesavapany, S.; Singleton, A.; Lees, A.; Harvey, R. J.; Harvey, K.; Cookson, M. R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis., 2006, 23, 329-41.
92. Smith, W. W.; Pei, Z.; Jiang, H.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 2006, 9, 1231-3.
93. Tan, E. K.; Zhao, Y.; Skipper, L.; Tan, M. G.; Di Fonzo, A.; Sun, L.; Fook-Chong, S.; Tang, S.; Chua, E.; Yuen, Y.; Tan, L.; Pavanni, R.; Wong, M. C.; Kolatkar, P.; Lu, C. S.; Bonifati, V.; Liu, J. J. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum. Genet., 2007, 120, 857-63.
94. Skipper, L.; Shen, H.; Chua, E.; Bonnard, C.; Kolatkar, P.; Tan, L. C. S.; Jamora, R. D.; Puvan, K.; Puong, K. Y.; Zhao, Y.; Pavanni, R.; Wong, M. C.; Yuen, Y.; Farrer, M.; Liu, J. J.; Tan, E. K. Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology, 2005, 65, 1319-21.
95. Abeliovich, A.; Beal, M. F. Parkinsonism genes: culprits and clues. J. Neurochem., 2006, 99, 1062-72.
96. Anglade, P.; Vyas, S.; Javoy-Agid, F.; Herrero, M. T.; Michel, P. P.; Marquez, L.; Mouatt-Priget, A.; Ruberg, M.; Hirsh, E. C.; Agid, Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol., 1997, 12, 25-31.
97. MacLeod, D.; Dowman, J.; Hammond, R.; Leete, T.; Inoue, K.; Abeliovich, A. The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology. Neuron, 2006, 52, 587-93.
98. Norris, E. H.; Giasson, B. I. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. Antioxid. Redox. Signal., 2005, 7, 672-84.
99. Dachsel, J. C.; Taylor, J. P.; Mok, S. S.; Ross, O. A.; Hinkle, K. M.; Bailey, R. M.; Hines, J. H.; Szutu, J.; Madden, B.; Petrucelli, L.; Farrer, M. J. Identification of potential protein interactors of Lrrk2. Parkinsonism. Relat. Disord., 2007, 13, 382-5.
100. Luo, G. R.; Chen, S.; Le, W. D. Are heat shock proteins therapeutic target for Parkinson's disease? Int. J. Biol. Sci., 2007, 3, 20-6.
101. Baldereschi, M.; Di Carlo, A.; Rocca, W. A.; Vanni, P.; Maggi, S.; Perissinotto, E.; Grigoletto, F.; Amaducci, L.; Inzitari, D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology, 2000, 55, 1358-63.
102. Van den Eeden, S. K.; Tanner, C. M.; Bernstein, A. L.; Fross, R. D.; Leimpeter, A.; Bloch, D. A.; Nelson, L. M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol., 2003, 157, 1015-22.
103. Cavazzoni, M.; Barogi, S.; Baracca, A.; Castelli, G. P.; Lenaz, G. The effect of aging and oxidative stress on peroxide levels and the mitochodrial membrane potential in isolated rat hepatocytes. FEBS. Letters, 1999, 449, 53-6.
104. Sofic, E.; Riederer, P.; Heinsen, H.; Beckmann, H.; Reynolds, G. P.; Hebenstreit, G.; Youdim, M. B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm., 1988, 74, 199-205.
105. Dexter, D. T.; Wells, F. R.; Agid, F.; Agid, Y.; Lees, A. J.; Jenner, P.; Marsden, C. D. Increased nigral iron content in postmortem parkinsonian brain. Lancet, 1987, 2, 1219-20.
106. Dickson, D. W. Linking Selective Vulnerability to Cell Death Mechanisms in Parkinson's Disease. Am. J. Pathol., 2007, 170, 75-86
107. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol., 2003, 53, S26-S36.
108. Lee, S. B.; Kim, W.; Lee, S.; Chung, J. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem. Biophys. Res. Commun., 2007, 358, 534-9.
109. Liu, Z.; Wang, X.; Yu, Y.; Li, X.; Wang, T.; Jiang, H.; Ren, Q.; Jiao, Y.; Sawa, A.; Moran, T.; Ross, C. A.; Montell, C.; Smith W. W. A Drosophila model for LRRK2-linked parkinsonism. Proc. Natl. Acad. Sci. USA, 2008, 105, 2693-8.
110. Abysalh, J. C.; Kuchnicki, L. L.; Larochelle, D. A. The identification of pats1, a novel gene locus required for cytokinesis in Dictyostelium discoideum. Mol. Biol. Cell, 2003, 14, 14-25.
111. Li, Y.; Liu, W.; Oo, T. F.; Wang, L.; Tang, Y.; Jackson-Lewis, V.; Zhou, C.; Geghman, K.; Bogdanov, M.; Przedborski, S.; Beal, M. F.; Burke, R. E.; Li, C. Mutant LRRK2 R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci., 2009, 12, 826-8.
112. Jaleel, M.; Nichols, R. J.; Deak, M.; Campbell, D. G.; Gillardon, F.; Knebel, A.; Alessi, D. R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's-disease mutants affect kinase activity. Biochem. J., 2007, 405, 307-17.
113. Häbig, K.; Walter, M.; Poths, S.; Riess, O.; Bonin, M. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics, 2008, 9, 83-94.
114. Lin, C. H.; Tan, E. K.; Chen, M. L.; Tan, L. C.; Lim, H. Q.; Chen, G. S.; Wu, R. M. Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. Neurology, 2008, 71, 1727-32.
115. Di Fonzo, A.; Chien, H. F.; Socal, M.; Giraudo, S.; Tassorelli, C.; Iliceto, G.; Fabbrini, G.; Marconi, R.; Fincati, E.; Abbruzzese, G.; Marini, P.; Squitieri, F.; Horstink, M. W.; Montagna, P.; Libera, A. D.; Stocchi, F.; Goldwurm, S.; Ferreira, J. J.; Meco, G.; Martignoni, E.; Lopiano, L.; Jardim, L. B.; Oostra, B. A.; Barbosa, E. R.; Bonifati, V. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 2007, 68, 1557-62.
116. Ramirez, A.; Heimbach, A.; Gründemann, J.; Stiller, B.; Hampshire, D.; Cid, L. P.; Goebel, I.; Mubaidin, A. F.; Wriekat, A. L.; Roeper, J.; Al-Din, A.; Hillmer, A. M.; Karsak, M.; Liss, B.; Woods, C. G.; Behrens, M. I.; Kubisch, C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet., 2006, 38, 1184-91.
117. Gitler, A. D.; Chesi, A.; Geddie, M. L.; Strathearn, K. E.; Hamamichi, S.; Hill, K. J.; Caldwell, K. A.; Caldwell, G. A.; Cooper, A. A.; Rochet, J. C.; Lindquist, S. α-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet., 2009, 41, 308-15.
118. Schultheis, P. J.; Hagen, T. T.; O'Toole, K. K.; Tachibana, A.; Burke, C. R.; McGill, D. L.; Okunade, G. W.; Shull, G. E. Characterization of the P5 subfamily of P-type transport ATPases in mice. Biochem. Biophys. Res. Commun., 2004, 323, 731-8.
119. Wei, J.; Fujita, M.; Nakai, M.; Waragai, M.; Watabe, K.; Akatsu, H.; Rockenstein, E.; Masliah, E.; Hashimoto, M. Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies. J. Biol. Chem., 2007, 282, 28904-14.
120. Bahr, B. A.; Bendiske, J. The neuropathogenic contributions of lysosomal dysfunction. J. Neurochem., 2002, 83, 481-9.
121. Jones, D. C.; Prabhakaran, K.; Li, L.; Gunasekar, P. G.; Shou, Y.; Borowitz, J. L.; Isom, G. E. Cyanide enhancement of dopamineinduced apoptosis in mesencephalic cells involves mitochondrial dysfunction and oxidative stress. Neurotoxicology, 2003, 24, 333-42.
122. Chu, C. Y.; Liu, Y. L.; Chiu, H. C.; Jee, S. H. Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. Br. J. Dermatol., 2006, 154, 1071-9.
123. Maker, H. S.; Weiss, C.; Silides, D. J.; Cohen, G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem., 1981, 36, 589-93.
124. Nair, V. D. Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Apoptosis, 2006, 11, 955-66.
125. Mogi, M.; Kondo, T.; Mizuno, Y.; Nagatsu, T. p53 protein, interferongamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci. Lett., 2007, 414, 94-7.
126. Perier, C.; Bové, J.; Wu, D. C.; Dehay, B.; Choi, D. K.; Jackson-Lewis, V.; Rathke-Hartlieb, S.; Bouillet, P.; Strasser, A.; Schulz, J. B.; Przedborski, S.; Vila, M. Two molecular pathways initiate mitochondriadependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2007, 104, 8161-6.
127. Duan, W.; Zhu, X.; Ladenheim, B.; Yu, Q. S.; Guo, Z.; Oyler, J.; Cutler, R. G.; Cadet, J. L.; Greig, N. H.; Mattson, M. P. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol., 2002, 52, 597-606.
128. Biswas, S. C.; Ryu, E.; Park, C.; Malagelada, C.; Greene, L. A. Puma and p53 play required roles in death evoked in a cellular model of parkinson disease. Neurochem. Res., 2005, 30, 839-45.
129. Steckley, D.; Karajgikar, M.; Dale, L. B.; Fuerth, B.; Swan, P.; Drummond-Main, C.; Poulter, M. O.; Ferguson, S. S.; Strasser, A.; Cregan, S. P. Puma is a dominant regulator of oxidative stress induced Bax activation and neuronal apoptosis. J. Neurosci., 2007, 27, 12989-99.
130. Gow, A. J.; Chen, Q.; Gole, M.; Themistocleous, M.; Lee, V. M.; Ischiropoulos, H. Two distinct mechanisms of nitric oxidemediated neuronal cell death show thiol dependency. Am. J. Physiol. Cell. Physiol., 2000, 278, 1099-07.
131. Beckman, J. S. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J. Dev. Physiol., 1991, 15, 53-9.
132. Hofseth, L. J.; Saito, S.; Hussain, S. P.; Espey, M. G.; Miranda, K. M.; Araki, Y.; Jhappan, C.; Higashimoto, Y.; He, P.; Linke, S. P.; Quezado, M. M.; Zurer, I.; Rotter, V.; Wink, D. A.; Appella, E.; Harris, C. C. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc. Natl. Acad. Sci. USA, 2003, 100, (1), 143-8.
133. Messmer, U. K.; Brüne, B. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. Biochem. J., 1996, 319, 299-05.
134. Shiloh, Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem. Sci., 2006, 31, 402-10.
135. Greene, L. A.; Biswas, S. C.; Liu, D. X. Cell cycle molecules and vertebrate neuron death: E2F at the hub. Cell. Death Differ., 2004, 11, 49-60.
136. Herrup, K.; Neve, R.; Ackerman, S. L.; Copani, A. Divide and die: cell cycle events as triggers of nerve cell death. J. Neurosci., 2004, 24, 9232-9.
137. Nakamura, Y. ATM: the p53 booster. Nat. Med., 1998, 4, 1231-32.
138. Siliciano, J. D.; Canman, C. E.; Taya, Y.; Sakaguchi, K.; Appella, E.; Kastan, M. B. DNA damage induces phosphorylation of the amino terminus of p53. Genes. Dev., 1997, 11, 3471-81.
139. Lee, S. J.; Kim, D. C.; Choi, B. H.; Ha, H.; Kim, K. T. Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death. J. Biol. Chem., 2006, 281, 2215-24.
140. Camins, A.; Verdaguer, E.; Folch, J.; Beas-Zarate, C.; Canudas, A. M.; Pallas, M. Inhibition of ataxia telangiectasia-p53-E2F-1 pathway in neurons as a target for the prevention of neuronal apoptosis. Curr. Drug Metab., 2007, 8, 709-15.
141. Borta, A.; Höglinger, G. U. Dopamine and adult neurogenesis. J. Neurochem., 2007, 100, 587-95.
142. Van Landingham, J. W.; Tassabehji, N. M.; Somers, R. C.; Levenson, C. W. Expression Profiling of p53-Target Genes in Copper-Mediated Neuronal Apoptosis. Neuro Mol. Med., 2005, 7, 311-24.
143. Bretaud, S.; Allen, C.; Ingham, P. W.; Bandmann, O. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J. Neurochem., 2007, 100, 1626-35.
144. Gomez-Lazaro, M.; Galindo, M. F.; Concannon, C. G.; Segura, M. F.;
145. Yang, W.; Tiffany-Castiglioni, E. Paraquat-induced apoptosis in human neuroblastoma SH-SY5Y cells: involvement of p53 and mitochondria. J. Toxicol. Environ. Health A., 2008, 71, 289-99.
146. Liang, Z. Q.; Li, Y. L.; Zhao, X. L.; Han, R.; Wang, X. X.; Wang, Y.; Chase, T. N.; Bennett, M. C.; Qin, Z. H. NF-kappa B contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res., 2007, 1145, 190-203.
147. Zhang, Y.; Gao, J.; Chung, K. K.; Huang, H.; Dawson, V. L.; Dawson, T. M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicleassociated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA, 2000, 97, 13354-9.
148. Dahlmann, B. Role of proteasomes in disease. BMC Biochem., 2007, 8 (Suppl 1), S3.
149. Imai, Y.; Soda, M.; Hatakeyama, S.; Akagi, T.; Hashikawa, T.; Nakayama, K. I.; Takahashi, R. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell, 2002, 10, 55-67.
150. Ito, H.; Kamei, K.; Iwamoto, I.; Inaguma, Y.; García-Mata, R.; Sztul, E.; Kato, K. Inhibition of proteasomes induces accumulation, phosphorylation, and recruitment of HSP27 and alphaB-crystallin to aggresomes. J. Biochem., 2002, 131, 593-603.
151. Garrido, C.; Solary, E. A role of HSPs in apoptosis through "protein triage"? Cell Death Differ., 2003, 10, 619-20.
152. Nair, V. D.; McNaught, K. P.; González-Maeso, J.; Sealfon, S. C.; Olanow, C. W. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem., 2006, 281, 39550-60.
153. Wu, Y. R.; Wang, C. K.; Chen, C. M.; Hsu, Y.; Lin, S. J.; Lin, Y. Y.; Fung. H. C.; Chang, K. H.; Lee-Chen, G. J. Analysis of heat-shock protein 70 gene polymorphisms and the risk of Parkinson's disease. Hum. Genet., 2004, 114, 236-41.
154. Uryu, K.; Richter-Landsberg, C.; Welch, W.; Sun, E.; Goldbaum, O.; Norris, E. H.; Pham, C. T.; Yazawa, I.; Hilburger, K.; Micsenyi, M.; Giasson, B. I.; Bonini, N. M.; Lee, V. M.; Trojanowski, J. Q. Convergence of heat shock protein 90 with ubiquitin in filamentous α-synuclein inclusions of α-synucleinopathies. Am. J. Pathol., 2006, 168, 947-61.
155. Calderwood, S. K.; Khaleque, M. A.; Sawyer, D. B.; Ciocca, D. R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci., 2006, 31, 164-72.
156. Han, X.; Wang, F.; Yao, W.; Xing, H.; Weng, D.; Song, X.; Chen, G.; Xi, L.; Zhu, T.; Zhou, J.; Xu, G.; Wang, S.; Meng, L.; Iadecola, C.; Wang, G.; Ma, D. Heat shock proteins and p53 play a critical role in K+ channel-mediated tumor cell proliferation and apoptosis. Apoptosis, 2007, 12, 1837-46.
157. Graner, M. W.; Bigner, D. D. Chaperone proteins and brain tumors: Potential targets and possible therapeutics. Neuro-oncology, 2005, 7, 260-77.